



## Catabasis Pharmaceuticals to Present at 2021 Webbush PacGrow Healthcare Conference

August 4, 2021

BOSTON--(BUSINESS WIRE)--Aug. 4, 2021-- [Catabasis Pharmaceuticals, Inc.](#) (NASDAQ:CATB), a biopharmaceutical company, today announced that Jill C. Milne, Ph.D., Chief Executive Officer, will be presenting during a fireside chat at the upcoming virtual Webbush PacGrow Healthcare Conference on Tuesday, August 10<sup>th</sup>, 2021 at 8:35am ET. The session entitled "HAE There- Development Landscape in Hereditary Angioedema (HAE)" will include an overview of the HAE treatment landscape, information about Catabasis's lead program QLS-215, and a Q&A session.

A webcast of the presentation will be available at the following link: <https://wsw.com/webcast/webbush39/panel11/2571740>, and will also be available in the investors section of the Company's website, [www.catabasis.com](http://www.catabasis.com), and will be archived for 30 days following the presentation.

### About Catabasis

At Catabasis Pharmaceuticals, our mission is to bring hope with life-changing therapies to patients and families affected by rare and niche diseases. Our lead program, QLS-215, is a monoclonal antibody inhibitor of plasma kallikrein in preclinical development for the treatment of hereditary angioedema.

View source version on [businesswire.com](https://www.businesswire.com/news/home/20210804005076/en/): <https://www.businesswire.com/news/home/20210804005076/en/>

### Investor relations:

Andrea Matthews

[investors@catabasis.com](mailto:investors@catabasis.com)

### Media:

Elizabeth Higgins

[media@catabasis.com](mailto:media@catabasis.com)

Source: Catabasis Pharmaceuticals, Inc.